Pan P - Search Results

1

Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.

Wang X, Pan P, Li Y, Li D, Hou T. Wang X, et al. Among authors: pan p. Mol Biosyst. 2014 May;10(5):1196-210. doi: 10.1039/c4mb00013g. Mol Biosyst. 2014. PMID: 24647611

2

Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.

Shen M, Zhou S, Li Y, Pan P, Zhang L, Hou T. Shen M, et al. Among authors: pan p. Mol Biosyst. 2013 Mar;9(3):361-74. doi: 10.1039/c2mb25408e. Epub 2013 Jan 23. Mol Biosyst. 2013. PMID: 23340525

3

Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches.

Pan P, Li Y, Yu H, Sun H, Hou T. Pan P, et al. J Chem Inf Model. 2013 Apr 22;53(4):997-1006. doi: 10.1021/ci400066x. Epub 2013 Apr 3. J Chem Inf Model. 2013. PMID: 23521602

4

Discovery of Rho-kinase inhibitors by docking-based virtual screening.

Shen M, Yu H, Li Y, Li P, Pan P, Zhou S, Zhang L, Li S, Lee SM, Hou T. Shen M, et al. Among authors: pan p. Mol Biosyst. 2013 Jun;9(6):1511-21. doi: 10.1039/c3mb00016h. Epub 2013 Apr 3. Mol Biosyst. 2013. PMID: 23549429

5

Development and evaluation of an integrated virtual screening strategy by combining molecular docking and pharmacophore searching based on multiple protein structures.

Tian S, Sun H, Li Y, Pan P, Li D, Hou T. Tian S, et al. Among authors: pan p. J Chem Inf Model. 2013 Oct 28;53(10):2743-56. doi: 10.1021/ci400382r. Epub 2013 Sep 24. J Chem Inf Model. 2013. PMID: 24010823

6

Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.

Pan P, Li L, Li Y, Li D, Hou T. Pan P, et al. Antiviral Res. 2013 Nov;100(2):356-64. doi: 10.1016/j.antiviral.2013.09.006. Epub 2013 Sep 19. Antiviral Res. 2013. PMID: 24055835

7

Advances in the development of Rho-associated protein kinase (ROCK) inhibitors.

Pan P, Shen M, Yu H, Li Y, Li D, Hou T. Pan P, et al. Drug Discov Today. 2013 Dec;18(23-24):1323-33. doi: 10.1016/j.drudis.2013.09.010. Epub 2013 Sep 25. Drug Discov Today. 2013. PMID: 24076262 Review.

8

Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.

Zhu J, Pan P, Li Y, Wang M, Li D, Cao B, Mao X, Hou T. Zhu J, et al. Among authors: pan p. Mol Biosyst. 2014 Mar 4;10(3):454-66. doi: 10.1039/c3mb70314b. Epub 2013 Dec 16. Mol Biosyst. 2014. PMID: 24336903

9

The competitive binding between inhibitors and substrates of HCV NS3/4A protease: a general mechanism of drug resistance.

Guan Y, Sun H, Li Y, Pan P, Li D, Hou T. Guan Y, et al. Among authors: pan p. Antiviral Res. 2014 Mar;103:60-70. doi: 10.1016/j.antiviral.2014.01.010. Epub 2014 Jan 23. Antiviral Res. 2014. PMID: 24462696

10

Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials.

Wang Y, Wang M, Qi H, Pan P, Hou T, Li J, He G, Zhang H. Wang Y, et al. Among authors: pan p. Drug Metab Dispos. 2014 Apr;42(4):782-95. doi: 10.1124/dmd.113.053793. Epub 2014 Jan 29. Drug Metab Dispos. 2014. PMID: 24476576

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,905 results

Search Page

Filters